Acute flaccid myelitis features differ in peak, nonpeak years

Acute flaccid myelitis features differ in peak, nonpeak years

January 17, 2020 Acute flaccid myelitis features differ in peak, nonpeak years (HealthDay)—Clinical and laboratory characteristics of acute flaccid myelitis (AFM) cases differ in peak and nonpeak years, according to a study published online Jan. 15 in Emerging Infectious Diseases , a publication of the U.S. Centers for Disease Control and Prevention. Noting that peaks of AFM cases have occurred biennially since 2014, Nilay McLaren, from the CDC in Atlanta, and colleagues examined whether AFM etiology differed between peak and nonpeak years. Clinical and laboratory characteristics were compared for AFM cases that occurred during peak years (2016 and 2018; 366 cases) and nonpeak years (2015 and 2017; 50 cases). The researchers found that AFM patients were younger in peak versus nonpeak years (median age, 5.2 versus 8.3 years). Compared with nonpeak years, in peak years, a higher percentage of patients had pleocytosis (86 versus 60 percent), upper-extremity involvement (33 versus 16 percent), and an illness preceding limb weakness (90 versus 62 percent); in addition, more patients were positive for enterovirus or rhinovirus RNA in peak years (38 versus 16 percent). In peak years only, enterovirus D68 infection was associated with AFM. "The alternate-year pattern in peak AFM activity since 2014 highlights a noteworthy shift in the epidemiology of this syndrome," the authors write. "Differences between AFM cases in peak years and nonpeak years provide additional evidence to support the hypothesis of a unique pathogen or pathogens contributing to this new epidemiology." Explore further



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More